Karl Lewis, MD, on a Phase II Study of Cemiplimab for Basal Cell Carcinoma

Posted: Saturday, October 20, 2018

Karl Lewis, MD, of the University of Colorado, discusses a phase II study of cemiplimab in patients with advanced basal cell carcinoma. Patients in the trial experienced progression of disease on, or were intolerant of, prior hedgehog pathway inhibitor therapy.

For more information about this ongoing trial, visit clinicaltrials.gov

ClinicalTrials.gov ID: NCT03132636